PEN:NYE-Penumbra Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 233.3

Change

0.00 (0.00)%

Market Cap

USD 7.95B

Volume

0.49M

Analyst Target

USD 252.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 205.71B
MDT Medtronic PLC

N/A

USD 118.35B
STE STERIS plc

N/A

USD 21.88B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 21.28B
SNN Smith & Nephew SNATS Inc

N/A

USD 12.71B
BIO Bio-Rad Laboratories Inc

N/A

USD 10.14B
GMED Globus Medical

N/A

USD 10.01B
GKOS Glaukos Corp

N/A

USD 7.18B
INSP Inspire Medical Systems Inc

N/A

USD 5.82B
ITGR Integer Holdings Corp

N/A

USD 4.24B

ETFs Containing PEN

XHE SPDR® S&P Health Care Eq.. 2.03 % 0.35 %

N/A

USD 0.21B
DOCG:LSE L&G Healthcare Breakthrou.. 1.70 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.70 % 0.00 %

N/A

USD 0.07B
PAMC Pacer Lunt MidCap Multi-F.. 1.23 % 0.00 %

N/A

USD 0.06B
BWZ SPDR® Bloomberg Short Te.. 0.00 % 0.35 %

N/A

N/A
EPU iShares MSCI Peru ETF 0.00 % 0.59 %

N/A

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.25% 60% D- 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.25% 60% D- 27% F
Trailing 12 Months  
Capital Gain 17.91% 67% D+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.91% 67% D+ 60% D-
Trailing 5 Years  
Capital Gain 42.25% 74% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.25% 74% C 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.97% 65% D 73% C
Dividend Return 12.97% 65% D 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.84% 29% F 19% F
Risk Adjusted Return 27.10% 61% D- 44% F
Market Capitalization 7.95B 73% C 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.